CHICAGO, Feb. 19, 2025 /PRNewswire/ — As hospitals and health systems navigate increasing financial and operational pressures, improving organizational efficiency in surgical services has become a top priority.
Surgical Directions, the leader in perioperative and procedural care consulting, has identified key strategies to help hospitals achieve sustainable efficiency gains in 2025. By leveraging advanced analytics, workforce optimization, and collaborative governance models, health systems can improve patient throughput, optimize staffing, and enhance financial performance.
Key Solutions for Improving Organizational Efficiency
“High performance in surgical services is not about cutting corners—it’s about leveraging the right workflows, technology, and governance structures to empower your people and improve patient care,” said Leslie Basham, President & CEO of Surgical Directions. “Hospitals that prioritize organizational efficiency in 2025 will be best positioned for long-term success.”
ABOUT SURGICAL DIRECTIONS
Surgical Directions is a healthcare solutions company that helps health systems, provider groups and ASCs improve perioperative, procedural care and anesthesia services through consulting, technology, and leadership. We partner with organizations using peer-to-peer leadership, process expertise and predictive analytics to profitably grow their organizations. Our team of experienced practitioners and consultants tackles critical issues while achieving financial, operational, and clinical outcome excellence. Surgical Directions has successfully served 500 clients to increase patient access and, most importantly, improve patient care. Additional information is available at www.surgicaldirections.com.
SOURCE Surgical Directions
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…